|
|
 Previous Article | Table of Contents | Next Article 
Interleukin-6 gene expression in multiple myeloma: a characteristic of
immature tumor cells
H Hata, H Xiao, MT Petrucci, J Woodliff, R Chang and J Epstein
Department of Medicine, University of Arkansas for Medical Sciences, Little
Rock.
Interleukin-6 (IL-6) has been suggested to play a major role in multiple
myeloma. To investigate the source and target cells of IL-6 activity in
multiple myeloma, expression of the cytokine and its receptor genes by
myeloma plasma cells was studied. Tumor cells were sorted from bone marrow
aspirates of myeloma patients using 4-parameter gating. Myeloma cells were
identified as CD38high CD45negative- intermediate and by their
light-scatter characteristics. Sorted cells contained only myeloma plasma
cells. No contaminating cells were present as determined morphologically,
by monoclonal cytoplasmic Ig analysis, and by polymerase chain reaction
(PCR) amplification of marker genes. Myeloma cells from 45% of patients
expressed IL-6. IL-6 receptor transcripts were found in 68% of the
specimens. IL-6 gene expression correlated with expression of the IL-6
receptor gene (P < .005). Correlations observed between the expression
of CD45, a protein tyrosine phosphatase expressed by B lymphocytes but not
by plasma cells, and the expression of the IL-6 and IL-6-receptor genes (P
< .0002 and P < .005, respectively) suggest that an autocrine IL-6
loop is functioning in myeloma in preplasma cells.
Volume 81,
Issue 12,
pp. 3357-3364,
06/15/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Moreaux, F. W. Cremer, T. Reme, M. Raab, K. Mahtouk, P. Kaukel, V. Pantesco, J. De Vos, E. Jourdan, A. Jauch, et al.
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature
Blood,
August 1, 2005;
106(3):
1021 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Robillard, C. Pellat-Deceunynck, and R. Bataille
Phenotypic characterization of the human myeloma cell growth fraction
Blood,
June 15, 2005;
105(12):
4845 - 4848.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, M. J. Wezeman, A. Henderson, M. Cottler-Fox, Q. Yi, B. Barlogie, and J. Epstein
Cancer and the Microenvironment: Myeloma-Osteoclast Interactions as a Model
Cancer Res.,
March 15, 2004;
64(6):
2016 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asosingh, A. Willems, I. Van Riet, B. Van Camp, and K. Vanderkerken
Delayed in Vivo Disease Progression Is Associated with High Proportions of CD45+ Myeloma Cells in the 5T2MM Murine Model
Cancer Res.,
June 15, 2003;
63(12):
3019 - 3020.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Asosingh, H. De Raeve, I. Van Riet, B. Van Camp, and K. Vanderkerken
Multiple myeloma tumor progression in the 5T2MM murine model is a multistage and dynamic process of differentiation, proliferation, invasion, and apoptosis
Blood,
April 15, 2003;
101(8):
3136 - 3141.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, C. L. Johnson, S. C. Mahaffey, M. J. Wezeman, B. Barlogie, and J. Epstein
Antimyeloma efficacy of thalidomide in the SCID-hu model
Blood,
December 1, 2002;
100(12):
4162 - 4168.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A. Frassanito, A. Cusmai, G. Iodice, and F. Dammacco
Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis
Blood,
January 15, 2001;
97(2):
483 - 489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, J. A. L. Fenton, J. Ashcroft, A. English, R. A. Jones, S. J. Richards, G. Pratt, R. Owen, F. E. Davies, J. A. Child, et al.
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells
Blood,
December 1, 2000;
96(12):
3880 - 3886.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Pope, R. D. Brown, J. Gibson, E. Yuen, and D. Joshua
B7-2-positive myeloma: incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy
Blood,
August 15, 2000;
96(4):
1274 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Nakayama, J. Kitayama, T. Muto, and H. Nagawa
Characterization of Intracellular Cytokine Profile of CD4(+) T Cells in Peripheral Blood and Tumor-draining Lymph Nodes of Patients with Gastrointestinal Cancer
Jpn. J. Clin. Oncol.,
July 1, 2000;
30(7):
301 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. E. Barton, J. Cullison, J. Jackson, and T. Murphy
A Model that Reproduces Syndromes Associated with Human Multiple Myeloma in Nonirradiated SCID Mice
Experimental Biology and Medicine,
February 1, 2000;
223(2):
190 - 197.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
S. Yaccoby and J. Epstein
The Proliferative Potential of Myeloma Plasma Cells Manifest in the SCID-hu Host
Blood,
November 15, 1999;
94(10):
3576 - 3582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Thabard, S. Barille, M. Collette, J.-L. Harousseau, M.-J. Rapp, R. Bataille, and M. Amiot
Myeloma Cells Release Soluble Interleukin-6R{{alpha}} in Relation to Disease Progression by Two Distinct Mechanisms: Alternative Splicing and Proteolytic Cleavage
Clin. Cancer Res.,
October 1, 1999;
5(10):
2693 - 2697.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Feinman, J. Koury, M. Thames, B. Barlogie, J. Epstein, and D. S. Siegel
Role of NF-kappa B in the Rescue of Multiple Myeloma Cells From Glucocorticoid-Induced Apoptosis by Bcl-2
Blood,
May 1, 1999;
93(9):
3044 - 3052.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Yaccoby, B. Barlogie, and J. Epstein
Primary Myeloma Cells Growing in SCID-hu Mice: A Model for Studying the Biology and Treatment of Myeloma and Its Manifestations
Blood,
October 15, 1998;
92(8):
2908 - 2913.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Jennings and K. A. Foon
Recent Advances in Flow Cytometry: Application to the Diagnosis of Hematologic Malignancy
Blood,
October 15, 1997;
90(8):
2863 - 2892.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Beck, S.-M. Hsu, J. Wijdenes, R. Bataille, B. Klein, D. Vesole, K. Hayden, S. Jagannath, and B. Barlogie
Alleviation of Systemic Manifestations of Castleman's Disease by Monoclonal Anti-Interleukin-6 Antibody
N. Engl. J. Med.,
March 3, 1994;
330(9):
602 - 605.
[Full Text]
|
|
|
|
|
